Georg Hess

11PUBLICATIONS
68CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumoursHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 16, 2026
Healthcare resource utilization analysis in newly diagnosed mantle cell lymphoma: resource alleviation with adoption of the TRIANGLE ibrutinib regimen without autologous stem cell transplantation.

|Sep 18, 2023
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.

Loretta J Nastoupil, Georg Hess, Miguel A Pavlovsky

|Oct 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.

Georg Hess, Martin Dreyling, Lucie Oberic

|May 25, 2022
Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.

Svenja Petersohn, Gilles Salles, Michael Wang

|May 13, 2022
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.

Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski

|Apr 01, 2022
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.

Georg Hess, Andreas Hüttmann, Mathias Witzens-Harig

Pageof 2

Frequent Collaborators

2 joint publications

Pier Luigi Zinzani

2 joint publications

Gilles Salles

1 joint publications

Igor Aurer

1 joint publications

Mats Jerkeman